rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lexicon Pharmaceuticals, Inc.

LXRX · Nasdaq

Health CareBiotechnologyNot moving yet

LXRX stood above a rising 150-day average in 44 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 24.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$5.4M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
144 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$5.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Raymond DebbaneDirectorbought2,000at $1.4925 Feb 2026filed 27 Feb 2026
Raymond DebbaneDirectorbought100,000at $1.4723 Feb 2026filed 25 Feb 2026
Raymond DebbaneDirectorbought100,000at $1.4820 Feb 2026filed 23 Feb 2026
Raymond DebbaneDirectorbought50,000at $1.4419 Feb 2026filed 23 Feb 2026
Raymond DebbaneDirectorbought133,688at $1.3218 Feb 2026filed 18 Feb 2026
Raymond DebbaneDirectorbought76,857at $1.3117 Feb 2026filed 18 Feb 2026
Raymond DebbaneDirectorbought57,952at $1.3113 Feb 2026filed 18 Feb 2026
Invus Global Management, LlcDirector, 10% ownerbought1,538,462at $1.302 Feb 2026filed 4 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders144+16 on the quarter
New · exited44 · 29
Reported value$875.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Artal Group S.A.added · filed 13 Aug 2026175,156,062$420.4M+20,421,735+13.2%
FMR LLCadded · filed 13 Aug 202651,782,045$124.3M+6,725,707+14.9%
Siren, L.L.C.unchanged · filed 13 Aug 202644,303,518$106.3M00.0%
Sessa Capital IM, L.P.added · filed 14 Aug 202618,960,836$45.5M+1,047,875+5.8%
BlackRock, Inc.added · filed 7 Aug 202617,348,741$41.6M+14,026,522+422.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20269,901,208$23.8M+382,041+4.0%
Point72 Asset Management, L.P.added · filed 14 Aug 20268,251,325$19.8M+436,719+5.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20266,244,372$15.0M+3,075,261+97.0%
STATE STREET CORPadded · filed 7 Aug 20264,917,769$11.8M+3,953,731+410.1%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20262,357,749$5.7M+1,811,149+331.3%
31 Mar 2023 – 30 Jun 2026
78110142Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Christopher J. Sobecki Company insiderDirector · last 3 Jun 20262 · 0
Diane E. Sullivan Company insiderDirector · last 3 Jun 20260 · 0
Ivan Cheung Company insiderDirector · last 3 Jun 20260 · 0
Judith L. Swain Company insiderDirector · last 3 Jun 20260 · 0
Philippe Amouyal Company insiderDirector · last 3 Jun 20261 · 0
Raymond Debbane Company insiderDirector · last 3 Jun 202618 · 0
Sam L. Barker Company insiderDirector · last 3 Jun 20264 · 0
Artal Participations S.a r.l. Company insiderDirector, 10% owner · last 30 Apr 20260 · 0
Brian T. Crum Company insiderSVP, General Counsel & Secr. · last 28 Feb 20260 · 0
Craig B. Granowitz Company insiderSVP, Chief Medical Officer · last 28 Feb 20260 · 0
Lisa DeFrancesco Company insiderSVP, IR and Corp Comm · last 28 Feb 20260 · 0
Michael Exton Company insiderChief Executive Officer · last 28 Feb 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202599.4%
Operating profit marginFY 2025 · to 31 Dec 2025-98.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-136%
Return on capital employedFY 2025 · to 31 Dec 2025-29.8%
Debt to equityFY 2025 · to 31 Dec 20250.50×
Research spendFY 2025 · to 31 Dec 2025123%
Share count trendFY 2025 · to 4 Mar 202615.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$34.3M
Free cash flowFY 2025 · to 31 Dec 2025−$67.9M

Analyst forecasts

No analyst forecasts yet.